Role for interferon-γ inducible chemokines in endocrine autoimmunity: An expanding field
- 1 February 2003
- journal article
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 26 (2) , 177-180
- https://doi.org/10.1007/bf03345149
Abstract
The chemoattractant cytokines (chemokines) have been classified into 4 major subfamilies in relation to the position of the cysteine residues in their NH2 terminal portion. Interferon-γ inducible chemokines (CXCL9/Mig, CXCL10/IP-10, CXCL11/I-TAC), Strongly associated to Th1-me-diated immune responses, belong to the CXC sub-family. They represent an exception among chemokines in that they specifically interact with a single type of receptor, named CXCR3. A statisti-cally significant increase of CXCL10/IP-10 and CX-CL9/Mig expression, in thyroid tissue specimens obtained from subjects affected by Hashimoto’s thyroiditis and recent onset Graves’ disease has been reported. Furthermore, a statistically signif-icant increase in serumCXCL10/IP-10 levels has been found in newly diagnosed Graves’ patients when compared to healthy subjects as well as patients with long standing disease and a strong statistically significant inverse correlation between circulating CXCL10/IP-10 levels and disease dura-tion has been demonstrated. Similar findings have been obtained when Type 1 autoimmune diabetes affected patients have been taken into account. In conclusion, Such experiences have demonstrated an important role played by interferon-γ inducible CXC chemokines in the pathogenesis of glandular autoimmunity. In fact, it is reasonable to assume that glandular epithelial cells may modulate the autoimmune process at least in its initial phase, through the production of chemokines which induce migration of Th1 lymphocytes into the gland. Interferon-γ secretion by lymphocytes would, in turn, stimulate chemokines production by follicular cells, thus perpetuating the autoimmune cascade.Keywords
This publication has 11 references indexed in Scilit:
- Serum concentrations of the interferon-γ-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed Type I diabetes mellitus patients and subjects at risk of developing the diseaseDiabetologia, 2002
- Expression of IP-10/CXCL10 and MIG/CXCL9 in the Thyroid and Increased Levels of IP-10/CXCL10 in the Serum of Patients with Recent-Onset Graves' DiseaseThe American Journal of Pathology, 2002
- β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trialThe Lancet, 2001
- Thyrocytes from Autoimmune Thyroid Disorders Produce the Chemokines IP-10 And Mig and Attract CXCR3+ LymphocytesJournal of Clinical Endocrinology & Metabolism, 2001
- Involvement of chemokine receptors in breast cancer metastasisNature, 2001
- Elevated Serum IP-10 Levels Observed in Type 1 DiabetesDiabetes Care, 2001
- Cell cycle–dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activityJournal of Clinical Investigation, 2001
- The chemokine/chemokine-receptor family: potential and progress for therapeutic interventionCurrent Opinion in Chemical Biology, 2000
- The Biology of Chemokines and their ReceptorsAnnual Review of Immunology, 2000
- ChemokinesImmunity, 2000